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Abstract
Background: Peroxiredoxins (Prxs) have recently been suggested to have a role in tumorigenesis.
Methods: We studied the expression of Prx I-VI and their relationship to patient survival in 383 grade II-IV diffuse
astrocytic brain tumors.
Results: Prx I positivity was found in 68%, Prx II in 84%, Prx III in 90%, Prx IV in 5%, Prx V in 4% and Prx VI in 47%
of the tumors. Prx I and Prx II expression decreased significantly with increasing malignancy grade (p < 0.001 and
p < 0.001). Patients with Prx I or Prx II positive tumors were significantly younger than the average age of all the
patients (p = 0.014 and p = 0.005). A lower proliferation rate was associated with Prx I and Prx VI positive tumors
(p = 0.019 and p = 0.033), and a lower apoptotic rate was found within Prx I and Prx II positive tumors (p < 0.001
and p = 0.007). Patients with Prx I and Prx II positive tumors had a significantly better survival rate than their Prx-
negative counterparts (p = 0.0052 and p = 0.0002).
Conclusion: The expression of Prx I and Prx II correlates with astrocytic tumor features, such as grade and patient
age and proliferation activity (Prx I), and accordingly with patient survival.
Background
Diffusely infiltrating astrocytomas of grades II - IV are
the most frequent primary brain tumors accounting for
more than 30% of central nervous system tumors.
Although they may develop at any age, the majority of
astrocytomas manifest clinically in adults. Grade II
astrocytomas represent the least malignant cases,
whereas grades III (anaplastic astrocytomas) and IV
(glioblastomas or GBM) are highly malignant and have a
poor prognosis. GBM is one of the most aggressive
human neoplasms [1].
Peroxiredoxins (Prx) are a family of thiol-specific anti-
oxidant enzymes (AOE) that have a role in cellular anti-
oxidant defence by breaking down H202 [2,3]. Prxs are
also thought to be associated with cell proliferation,
apoptosis, differentiation, gene expression and resistance
to radiation or chemotherapy [4-8]. Microglial cells and
astrocytes have been shown weakly or moderately
immunoreactive for Prx I and Prx VI, and oligodendro-
cytes for Prx I and Prx IV. Neurons do not seem to
have immunoreactivity for Prx I and Prx VI, while all
other Prxs are expressed weakly to moderately [9].
Studies on human carcinomas of the thyroid gland,
pleural mesothelioma, oral and lung cancer, prostate
cancer and breast carcinoma suggest that Prxs may have
a role both in tumor progression and in drug resistance
[10-16]. It is also possible that Prx proteins have a direct
influence on tumorigenesis.
Overall the importance of the Prx family of proteins in
human tumors remains unclear. They have not been
earlier investigated in grade II-IV diffuse astrocytomas.
This prompted us to investigate the expression of all six
peroxiredoxins in 383 grade II-IV astrocytic brain
tumors and to examine how they correlate with tumor
features and patient survival.
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Methods
Tumor samples
Histological samples of astrocytic tumors were obtained
from 383 patients who underwent surgery at Tampere
University Hospital, Tampere, Finland in 1983-1997. 299
samples were from primary tumors and 84 from recur-
rent ones. Their distribution by malignancy grade is
shown in Table 1.
The median age of the patients at the time of opera-
tion was 48.9 years (mean 48.8, SD 15.0) and the male-
female ratio was 1.3:1. On average, patients with recur-
rent tumors were nine years younger than those with
primary tumors. All the patients underwent neurosurgi-
cal operation with the intention of gross radical tumor
resection. The patients with primary tumors that were
included to this study did not receive any anticancer
medication prior to the operation. The tumor samples
were fixed in 4% phosphate-buffered formaldehyde and
embedded in paraffin. Paraffin sections were stained
with haematoxylin-eosin. Histopathologic typing and
grading was carried out according to WHO criteria [1].
Histologically representative tumor regions were
selected by a neuropathologist (HH) and the samples
from these areas were applicated in tissue microarray
blocks using a custom-built instrument (Beecher Instru-
ments, Silver Spring, MD, USA). The diameter of the
tissue cores in the microarray blocks was 600 μm.
When assessing the role of malignancy grade, grade II
and III astrocytomas were considered as one group and
compared to glioblastomas (grade IV astrocytomas).
Immunohistology. The immunohistochemical (IHC)
procedure was as follows. Four-micron thick sections
were cut from the microarray blocks. The sections
were then deparaffinised in xylene and rehydrated in
descending ethanol series. For antigen retrieval, the
sections were incubated in 10 mM citrate buffer (pH
6.0) in a microwave oven, 2 min at 850 W followed by
8 min at 350 W. Endogenous peroxidase activity was
blocked by incubation in 0.1% hydrogen peroxide in
absolute methanol for 10 min. The polyclonal anti-Prx-
antibodies were a gift from Dr Kang (Center for Cell
Signalling Research and Division of Molecular Sciences,
Ewha Womans University, Seoul, Korea). The dilution
for the primary antibodies were 1:1500 for Prx I,
1:1000 for Prx II, 1:500 for Prx III, 1:1000 for Prx IV
and 1:2000 for Prxs V and VI. For positive controls we
used malignant mesothelioma samples previously
known to be positive [14]. Negative control staining
was carried out by substituting PBS and serum isotype
controls (Zymed Laboratories Inc.) for the primary
antibodies.
The primary antibodies for Prx I-VI were revealed
using the Histostain-Plus Kit (Zymed Laboratories Inc,
South San Francisco, CA) as described previously [17].
The immunohistochemical staining results were evalu-
ated for each immunohistochemical target during one
session on a multiheaded microscope by three observers
semiquantitatively by dividing the AOE, PRX or CA IX
staining reaction into four categories based on the reac-
tivity of the staining taking equally into account both
the intensity and extent of the staining: 0 = no immu-
nostaining present; 1 = weak immunostaining, < 10% of
the tumor tissue immunostained; 2 = moderate immu-
nostaining, 10-50% of the tumor tissue immunostained;
3 = strong immunostaining present, > 50% of the tumor
tissue immunostained. When Prx negativity or positivity
were under comparison, the four categories were divided
into two groups: the Prx negative group (Prx-) con-
tained negatively and weakly stained tumors and the Prx
positive group (Prx+) contained tumors showing moder-
ate or strong immunostaining.
Cell proliferation
For analysis of cell proliferation, a mouse monoclonal
antibody MIB-1 recognising the Ki-67 antigen was used
(Immunotech, S.A. Marseille, France) (dilution 1:40).
After immunostaining, the tissue sections were counter-
stained with methyl green. Proliferative activity was
reported as the percentage of immunopositive nuclei.
Analysis of all tumor cells was done with an image ana-
lysis system (CAS-200 TM Software, Becton Dickinson
& Co., USA) as described previously [18] (Figure 1.).
Table 1 Description of the astrocytic tumors: Association of Prx expression with tumor grade in the total material
Tumor grade Primary tumors Recurrent tumors Total PrxI
+/-
PrxII
+/-
PrxIII
+/-
PrxIV
+/-
PrxV
+/-
PrxVI
+/-
Grade II 48 14 62 17/30 34/12 25/22 -/47 -/47 5/40
Grade III 35 19 54 14/28 28/15 27/16 -/44 -/43 2/39
Grade IV 216 51 267 33/184 98/120 126/87 1/209 -/211 26/189
Total 299 84 383 64/242 160/147 178/125 1/300 -/301 33/268
* ** n.s. n.s. n.s. n.s.
Negative or weak staining was considered as Prx-negative expression (Prx-) and moderate or strong staining as Prx-positive expression (Prx+). * p < 0.001,
chi-square test
** p < 0.001, chi-square test
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Apoptotic rate
The activity of apoptosis was determined by TUNEL-
labelling. Deparaffinised tumor microarray tissue sections
were first digested with proteinase K (20 μg/ml) for 15
min. Apoptotic cells were demonstrated using ApopTag
In Situ Apoptosis Detection Kit (Oncor, Inc., Gaithers-
burg, MD, USA) according to the manufacturer’s instruc-
tions. In the terminal deoxynucleotidyl transferase nick
end labelling method, the recommended concentration
was reduced by 8-fold. Direct immunoperoxidase detec-
tion of digoxigenin labelled dUTP was followed by coun-
terstaining in methyl green [19] (Figure 1.).
Statistical analysis
The tests used for statistical analysis were all part of
SPSS 11.0 (SPSS Inc., Chicago, Illinois) for Windows
software. Chi-square tests-, t-tests, Mann-Whitney tests
were used, as well as multivariate analysis of variance
(ANOVA). The log-rank test and Cox multivariate ana-
lysis were used for analysis of prognostic factors. The
significance level was set at p < 0.05.
Ethics
The study design was approved by the Ethics committee
of Tampere University Hospital and the National
Authority for Medicolegal Affairs.
Results
Expression
The expression of Prxs I-VI was analyzed in 299 pri-
mary and 84 recurrent grade II-IV astrocytic tumors.
The distribution of immunopositivity for each Prx is
shown in Table 2. Examples of immunopositive samples
of Prx I, II, III and VI and immunonegative samples of
Prx IV and V are shown in Figure 2A-F.
The immunostaining intensity of each Prx in different
grades is shown in Figure 3. Higher grade tumors
showed a significant decrease in immunoreactivity for
Prx I and Prx II (p < 0.001 and p < 0.001, chi-square
tests). The distribution of malignancy grade in Prx+ and
Prx- groups is shown in Table 1.
Prx I was positive in 66% of primary tumors and in
75% of recurrent tumors (p = 0.008, chi-square test).
Similarly, Prx VI was positive in 45% of primary tumors
and in 54% recurrent tumors (p = 0.01, chi-square test).
Patients with Prx I+ and Prx II+ primary tumors were
significantly younger than their Prx- counterparts (p =
0.014 and p = 0.005, t-test) (Table 3).
We also studied the intercorrelation of Prxs. Prx I
positivity correlated significantly with Prx II and Prx III
positivity (p < 0.001 and p = 0.014, chi-square tests),
and Prx II positivity correlated significantly with Prx III
and Prx VI positivity (p = 0.005 and p = 0.031, chi-
square tests): these Prx+ tumors increased considerably
when the other Prxs expressed positivity.
Proliferation and apoptosis
In the total material the mean MIB-1 proliferation index
was 16.0 (SD 20.88) and median 9.7%. Proliferation
activity was compared between Prx+ and Prx- groups.
Prx I+ and Prx VI+ tumors had a significantly lower
proliferation rate than their IHC negative counterparts
(p = 0.019 and p = 0.033, Mann-Whitney test). In con-
trast, Prx III+ tumors had a marginally higher prolifera-
tion rate than Prx III- tumors (p = 0.056, Mann-
Whitney test). The results are compiled in Table 3.
Figure 1 Apoptotic rate marker TUNEL-labelling (A) and proliferation index marker MIB-1 (B) in astrocytic brain tumor samples.
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The mean for the TUNEL labelling index in the total
material was 9.6 (SD 15.2) and median 3.6. The tumor
apoptotic rate was decreased in Prx I+ and Prx II+
tumors (p < 0.001 and p = 0.007, Mann-Whitney tests)
(Table 3).
When the malignancy grades were divided into two
groups (grades II and III vs. grade IV) and analyzed
separately, the proliferation index differed significantly
in Prx III+ and Prx VI+ lower grade (II and III) astrocy-
tomas compared to their Prx III- and Prx VI- counter-
parts. The mean for Prx III+ tumors was 14.7 (median
4.1, SD 26.2); in Prx- counterparts it was 8.4 (median
3.0, SD 17.8) (p = 0.043, Mann-Whitney test). The
mean proliferation rate in Prx VI+ cases was 1.6 (med-
ian 2.2, SD 1.6) and in Prx VI- counterparts 12.1 (med-
ian 4.1, SD 22.4) (p = 0.016, Mann-Whitney test). There
was no statistically significant difference in the prolifera-
tion index when only GBMs were included in the analy-
sis, nor in the case of other Prxs.
The apoptotic rate differed significantly only in the
case of Prx I and in GBMs, when the lower grade astro-
cytomas and GBMs were analyzed separately. The mean
apoptotic rate for Prx I+ GBMs was 8.8 (median 3.6, SD
17.6) and for Prx I- GBMs 12.8 (median 7.1, SD 17.8)
(p = 0.009, Mann-Whitney test).
Survival
Only the primary cases were included in the survival
analysis.
When Prx+ and Prx- tumors were compared, patients
with Prx I+ and Prx II+ tumors showed better survival
rate than their negative counterparts, Prx I+ nearly sig-
nificantly and Prx II+ significantly (p = 0.0052 and p =
0.0002, log-rank tests) (Figures 3 and 4). Other peroxire-
doxins did not reach statistical significance.
A further survival analysis was carried out for the
patients with glioblastomas (N = 216) or lower grade
(grade II and III) astrocytoma (N = 83). The mean fol-
low-up for GBMs was 433 days (16.2% alive after mean
follow-up) and for lower grade astrocytomas 1645 days
(30.1% alive after mean follow-up). In this comparison,
Prx I had a favourable effect on prognosis in lower
grade astrocytomas (p = 0.0072, log-rank test). In GBMs
no corresponding statistical significance was found in
patient survival.
Proliferation index, patient age (in days), tumor grade,
sex and Prxs were included in the Cox multivariate ana-
lysis. Only patient age and tumor grade had independent
prognostic significance (p < 0.001, Odds ratio (OR) =
2.207 and p < 0.001, OR = 1.874).
Discussion
We investigated the role of Prxs in a large series of dif-
fusely infiltrating (grade II-IV) astrocytic brain tumors.
Prx I and Prx II in particular showed interesting associa-
tions with tumor features and patient survival. The
majority of the astrocytic tumors were positive for Prx I,
Prx II and Prx III, while Prxs IV-VI showed lower
expression. The proportion of Prx I and Prx II immuno-
positive tumors decreased with increasing malignancy
grade. However, Prx I was more frequent in recurrent
tumors than in primary ones. Prx I and Prx II were
associated with patient prognosis, patients with positive
tumors living significantly longer than their negative
counterparts.
Our results suggest that Prxs have a role in the beha-
vior of astrocytic brain tumors, a role that seems to go
beyond that of an antioxidant enzyme. This notion is
underscored by their very low H2O2 catalysing activity
and their tendency to be inactivated during the H2O2
catalytic process, even at very low concentrations of
H2O2 [20,21]. We are only beginning to understand the
many and varied functions of Prxs. Their versatility is
likely to be comparable to that of thioredoxins [22].
Prxs act as reductases for alkyl hydroperoxide, H2O2
and peroxynitrite, and they seem to regulate peroxide-
mediated signaling cascades as well as NF-B activation
[21,23,24]. Although classified as peroxidases, they
already are known to regulate mitogen-activated protein
kinase activity [25], and they are associated with cell
proliferation and growth control, differentiation,
immune responses, apoptosis and tumorigenesis, patho-
genesis of neurodegenerative disorders and resistance to
radiation and/or drug therapy [7,26-29]. They are
Table 2 Distribution of immunostaining intensity of peroxiredoxins in astrocytic tumor samples
Intensity of immunostaining/peroxiredoxin Negative Weak Moderate Strong Prx- group/
Prx+ group
Prx I 32% 47% 18% 3% 79%/21%
Prx II 16% 32% 30% 22% 48%/52%
Prx III 10% 31% 39% 20% 41%/59%
Prx IV 95% 5% < 1% - 100%/-
Prx V 96% 4% - - 100%/-
Prx VI 53% 36% 10% 1% 89%/11%
For the analyses, the four categories are further divided into two groups: The Prx negative group (Prx-) contains negatively and weakly stained tumors and Prx
positive group (Prx+) contains tumors showing moderate or strong immunostaining.
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Figure 2 Expression of peroxiredoxins I-VI in astrocytic brain tumors. Positive expression is seen as an immunohistological red staining in
nucleus of the astrocytoma cells (Prx I, A; Prx II, B and Prx VI, F) and in the cytoplasma (Prx III, C). Prx IV (D) and Prx V (E) stainings are negative.
The figure panel consist astrocytic brain tumors of various grades (grade II, B, F; grade III A, grade IV (gbm) C, D, E).
Järvelä et al. BMC Cancer 2010, 10:104
http://www.biomedcentral.com/1471-2407/10/104
Page 5 of 10
needed for Myc-mediated transformation and apoptosis
[5,30] and they may have a role in tumorgenesis, as they
are aberrantly overexpressed in several cancers [10-16].
The involvement of Prxs in these many cell functions is
important because NF-B, cell proliferation, differentia-
tion and apoptotic activity have been found to be char-
acteristically altered in astrocytomas and to have an
effect on tumor behavior or even on prognosis [31-33].
Genes of Prxs can be induced by cellular stresses,
including hypoxia and rapid growth, which are typical of
aggressive tumors such as astrocytomas and particularly
GBMs. This could explain the association between dif-
ferent antioxidants in rapidly growing malignancies:
changes in the cellular environment affect the expres-
sion of more than one antioxidant enzyme at the same
time. The same phenomenon may be caused by
advanced treatments of the cancer: radiation or cyto-
toxic drugs, which often generate reactive oxygen meta-
bolites (e.g. cisplatin), cause oxidant stress at the cellular
level with consequent effects on the antioxidant machin-
ery; in some cases this may contribute to increased
resistance to such therapies. Resistance to anticancer
drugs and radiation therapy has already been reported
by Park and colleagues and Chung and colleagues in the
case of Prx II in gastric and head and neck cancer cell
lines [7,8].
In our astrocytoma material we found several correla-
tions of Prx I with tumor features and even with patient
survival. Patients with Prx I immunopositive tumors
were younger and they also lived longer. Furthermore,
compared to patients whose tumors did not express Prx
I, their tumors showed a lower proliferation rate and on
the other hand decreased apoptotic activity. However,
this seemingly contradictory result in prognosis and
apoptotic rate makes perfect sense when the tumors are
divided into two groups not only on the basis of their
Prx I status but also their histopathology. The beneficial
connection between Prx I positivity and prognosis was
significant mainly in grade II and III astrocytomas,
whereas no such statistically significant association was
seen in GBMs. At the same time the decreasing effect of
Prx I positivity on the apoptotic rate was significant
only in glioblastomas when the histopathology of the
tumor was taken into account. Even though it would be
favorable for the prognosis to have a higher apoptotic
rate, GBMs are known to be maximally aggressive and
rapidly growing tumors, so the effect on apoptosis
would need to be very high in order to be reflected in
the prognosis. In the case of grade II and III astrocytic
tumors, the effect of Prx I on the prognosis do not
seem to correlate with apoptosis. Prx I did correlate
with tumor malignancy grade, but it was not an
Figure 3 Survival by peroxiredoxin I in primary astrocytic brain tumors. Tumors were divided in two groups, Prx+ and Prx-. The difference
between the groups is significant (p = 0.0052, log-rank test).
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independent prognostic factor. Nevertheless, the associa-
tion of Prx I with malignancy grade and proliferation
suggests that Prx I, partly via its association with these
factors, has a role in the pathogenesis of grade II-III
astrocytomas.
In normal mammalian brain immunoreactivity for Prx
II has been found principally in the cytosol of most neu-
rons of grey matter [9,34,35]. It has also been found in
the nuclei of medial habenular neurons [9]. These are
involved in many important and even vital biological
functions, and the nuclear localisation of Prx II indicates
that it may have a role that goes beyond that of an anti-
oxidative protein in normal neural tissue. Furthermore,
Prx II seems to have several important independent
functions in various other human cells. For example,
lack of its expression is known to damage severely the
normal function of erythrocytes [35]. In the pathogen-
esis of neurodegenerative disorders, including Alzhei-
mer’s disease, Pick’s disease and Down syndrome [27],
the expression of Prx II is known to be aberrant.
Elevated Prx II expression has also been reported at
least in lung carcinoma and pleural mesothelioma
[13,14], and it is known to affect radiation sensitivity
and drug resistance [7,8].
In our material Prx II was associated with the tumor
apoptotic rate and the grade of malignancy. Like in the
case of Prx I, univariate analysis showed that Prx II had a
significant effect on prognosis. However, the median age
of the patients with Prx I and Prx II-positive tumors was
significantly less than of their Prx-negative counterparts
and thus explains part of this favorable effect to prognosis.
Prx II positivity was found in the vast majority of
tumors (in 84%), and Prx II seemed to be expressed to a
greater extent that has been reported previously in nor-
mal brain tissue, for example in the study of Sarafian
[34]. In that study Prx II was found exclusively in neu-
rons and hardly at all in glial cells. The upregulation of
Prx II could thus be a sign of an ultimate attempt of
growing astrocytoma cells to react to the cellular stress
and to resulting hypoxia/redox imbalance in the tissue.
Table 3 Expression of Prx, association with patient and tumor characteristics.
Characteristic PrxI
+/-
PrxII
+/-
PrxIII
+/-
PrxIV
+/-
PrxV
+/-
PrxVI
+/-
PATIENT
Age
Mean 45.0/52.5 47.9/54.6 51.8/50.2 #/50.9 #/51.1 52.9/51.0
Median 39.8/54.4 45.6/56.3 54.1/51.9 #/53.8 #/53.9 56.8/53.5
p = 0.014* p = 0.005* n.s. n.s.
Sex
Male 37/118 86/70 101/56 1/154 #/156 13/139
Female 21/93 55/59 59/51 -/110 #/110 12/102
n.s. n.s. n.s. n.s. n.s.
Recurrences
None 42/193 117/118 136/96 1/229 #/231 29/201
≥ 1 22/49 43/49 42/29 -/71 #/70 4/67
p = 0.015** n.s. n.s. n.s. n.s.
Tumor proliferation
(MIB-1)
Mean
SD 13.8/16.9 16.2/16.5 17.5/15.2 #/16.5 #/16.4 11.1/16.8
Median 23.7/21.6 24.5/18.9 22.7/22.3 #/22.2 #/22.2 18.1/22.0
5.0/10.4 8.2/12.2 10.6/7.1 #/9.4 #/9.4 5.0/10.0
p = 0.019*** n.s. p = 0.056**** p = 0.033***
Tumor
Apoptosis
Mean 5.5/10.4 7.6/11.6 8.7/10.7 #/9.6 #/9.6 8.9/9.4
SD 12.1/15.9 12.7/17.9 13.5/18.0 #/15.2 #/15.2 14.2/15.6
Median 3.6/7.1 3.6/7.1 3.6/3.6 #/3.6 #/3.6 3.6/3.6
p < 0.001*** p = 0.007*** n.s. n.s.
* T-test, only primary tumors were included
** Chi-square test
*** Mann-Whitney test
**** Near-significant p-value by Mann-Whitney test
# No cases in prx-positive group, analysis of significance not possible
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Prx III was expressed in 90% of astrocytomas being
the most often expressed peroxiredoxin in our study. In
grade II-III astrocytomas it was associated with a higher
proliferation rate, but there was no straightforward asso-
ciation with apoptosis. In normal brain tissue its immu-
noreactivity is concentrated to neurons especially in the
hippocampal area, where it has a protective role against
excitotoxic injuries [9,36]. The uneven concentration of
Prx III immunoreactivity in hippocampus results not
only from its function, but derives from its subcellular
localisation in mitochondria. It has been suggested that
Prx III is a critical regulator of apoptotic signalling by
virtue of its regulatory effect on the abundance of mito-
chondrial H2O2 [37]. In our material this association
was not evident.
Only a few cases were immunoreactive for Prx IV and
Prx V in our material. In normal mammalian brain tissue,
moderate Prx IV immunoreactivity has been reported in
the cytoplasm of neurons and strong, mainly nuclear
positivity in oligodendrocytes [9]. This could mean that
Prx IV has at least partially different roles in these cells.
Based on our results, it seems that Prx IV is not abun-
dant in neoplastic astrocytes. This is also the case with
Prx V, which is found in normal neural tissue in mouse
brain [9] and is known to have a protective role against
excitotoxic brain lesions in newborn mice [38].
Prx VI immunoreactivity has been previously found in
normal mouse astrocytes and oligodendrocytes. Interest-
ingly, the Prx VI protein has been shown to be
expressed in the nuclei of astrocytes and oligodendro-
cytes, although Prx VI is known to be cytosolic in other
mammalian cells (e.g. [9,21]). This could mean that Prx
VI carries out a different function in the neural system
than in other organs, such as the lungs and kidneys,
where it has been previously reported to be found in the
cytosol [39]. In our material almost half of the tumors
showed immunoreactivity for Prx VI, most of them
faintly or moderately. In recurrent tumors the propor-
tion of immunopositive tumors increased significantly.
In addition, Prx VI positive tumors showed a lower pro-
liferation rate than negative ones, especially in grade II
and III gliomas.
The biological functions and regulation of Prxs seem
to be quite complex. This became more evident in a
reverse transcription polymerase chain reaction analysis
in which we studied PrxI, Prx II and Prx III mRNA
levels in six frozen tumor specimens. Like in many
other cases noticed in our laboratory, the mRNA and
protein expression levels do not always correlate well
with each other in biological models. This phenomenon
was again confirmed here since we found no solid corre-
lation between the studied Prx mRNA and protein
Figure 4 Survival by peroxiredoxin II in primary astrocytic brain tumors. Tumors were divided in two groups, Prx+ and Prx-. The difference
between the groups is significant (p = 0.0002, log-rank test).
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expression levels. Although the sample size in the
mRNA analysis was too small to make any final conclu-
sions, we consider the semiquantitative assessment of
immunostaining reactivity a more reliable marker for
the actual protein expression level.
To our knowledge, there is only few studies, and with
limited number of cases, concerning the role of Prxs in
astrocytomas. The study of Odreman [40] showed partly
contradictory data to our results. In their study 10 fibril-
lary astrocytomas of grade II-III and 10 glioblastomas
were analyzed for their Prx I and Prx VI protein pattern
by 2D electrophoresis. They used Western and immuno-
histochemical analysis to confirm the differential expres-
sion of the identified proteins. The expression of both
Prx I and Prx VI was found to be significantly stronger
in high-grade tumors compared to low-grade tumors
[40]. In our considerably larger study of 383 astrocyto-
mas Prx I was more frequently expressed in grade II
and III tumors when compared to GBMs, but Prx VI
expression did not have any statistically significant dif-
ference between these grades.
Conclusions
In conclusion, our results suggest that the family of Prxs
has an important role in the biology of astrocytomas.
Especially Prx I and Prx II expression seemed to have
correlation with the malignancy of astrocytic cells. They
correlated with cell proliferation, apoptosis and malig-
nancy grade, the main features of tumors for diagnostic
and prognostic purposes. They also had an association
with patient age and in univariate analysis with patient
survival. Even though the correlation with prognosis
may be explained by the association with other features
(age, grade), Prx I and Prx II seemed to be important in
tumorigenesis of astrocytic tumors.
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